Tezepelumab Demonstrates Robust Efficacy and Safety Across Diverse Severe Asthma Phenotypes: Insights from the Phase 4 PASSAGE Study

Highlight

• Tezepelumab markedly reduced annualized asthma exacerbation rate (AAER) by 70% in a diverse, real-world US cohort with severe uncontrolled asthma (SUA).
• Significant improvements in lung function (FEV1) and quality of life measures were noted across diverse asthma phenotypes, including low eosinophil counts and allergic status.
• Underrepresented populations—Black/African American patients, adolescents, those with smoking history, and comorbid COPD—experienced similarly substantial benefits.
• No new safety concerns emerged over 12 months, supporting tezepelumab’s favorable risk-benefit profile in heterogeneous SUA patients.

Study Background